{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Encompass Health Corp.
Is Encompass Health Corp. technically bullish or bearish?
As of October 31, 2025, Encompass Health Corp. shows a mildly bullish trend with mixed weekly indicators, having outperformed the S&P 500 year-to-date but lagged over the past year, suggesting a cautious bullish outlook.
Is Encompass Health Corp. technically bullish or bearish?
As of October 31, 2025, Encompass Health Corp. shows a mildly bullish trend overall, with mixed signals from various indicators, having underperformed the S&P 500 recently but outperformed it year-to-date and over longer periods.
Encompass Health Stock Hits Day Low of $107.52 Amid Price Pressure
Encompass Health Corp. saw a notable decline in stock value, contrasting with the stable performance of the S&P 500. Despite recent short-term losses, the company has achieved a strong year-to-date performance and consistent returns over the past three years, supported by high management efficiency and robust cash flow.
Encompass Health Opens Weak with 9.91% Gap Down Amid Market Concerns
Encompass Health Corp. experienced a notable decline in its stock performance, contrasting with the stable S&P 500. The company, with a market cap of approximately USD 14.5 billion, maintains a strong dividend yield and return on equity, reflecting solid profitability. Technical indicators suggest mixed trends in its performance.
Encompass Health Corp. Hits New 52-Week High of $127.99
Encompass Health Corp. achieved a new 52-week high of USD 127.99 on October 24, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has a market capitalization of USD 14,505 million, a P/E ratio of 21.00, and a notable dividend yield of 23.73%.
Is Encompass Health Corp. overvalued or undervalued?
As of October 17, 2025, Encompass Health Corp. is considered an attractive investment due to its undervaluation indicated by a P/E ratio of 21, a PEG ratio of 0.71, an EV to EBITDA ratio of 13.02, strong year-to-date performance of 34.87%, a high dividend yield of 35.19%, and a robust ROE of 30.29%.
Encompass Health Corp. Experiences Valuation Adjustment Amid Strong Market Performance Indicators
Encompass Health Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation metrics, including a P/E ratio of 21 and a price-to-book value of 6.49. The company has outperformed the S&P 500 in year-to-date and three-year returns, indicating strong operational efficiency and competitive positioning.
Is Encompass Health Corp. overvalued or undervalued?
As of October 17, 2025, Encompass Health Corp. is considered undervalued with a P/E ratio of 21, a PEG ratio of 0.71, and strong performance metrics, indicating an attractive investment opportunity compared to its peers.
Encompass Health Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Encompass Health Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has shown strong performance with a 26.40% return over the past year, outperforming the S&P 500. The stock has experienced volatility, with a 52-week high of $127.86 and a low of $87.85, reflecting its market resilience.
Is Encompass Health Corp. technically bullish or bearish?
As of October 10, 2025, Encompass Health Corp. has a mildly bullish technical trend, supported by a bullish monthly MACD and Bollinger Bands, despite a mildly bearish weekly MACD and Dow Theory.
Encompass Health Corp. Hits New 52-Week High at $127.86
Encompass Health Corp. has achieved a new 52-week high, reflecting a strong performance with a notable increase over the past year. The company, with a market capitalization of USD 14,505 million, features a solid P/E ratio and an attractive dividend yield, showcasing its financial stability and growth potential.
Is Encompass Health Corp. technically bullish or bearish?
As of August 7, 2025, Encompass Health Corp. shows a bullish trend supported by strong indicators, despite some mixed signals in the short term, having outperformed the S&P 500 with a year-to-date return of 35.71%.
Is Encompass Health Corp. overvalued or undervalued?
As of July 29, 2025, Encompass Health Corp. is considered undervalued with an attractive valuation grade, supported by a P/E ratio of 21, an EV to EBITDA of 13.02, and a PEG ratio of 0.71, outperforming peers and the S&P 500 with a year-to-date return of 35.71%.
Is Encompass Health Corp. technically bullish or bearish?
As of April 23, 2025, the technical trend has shifted to bullish, supported by strong indicators like a bullish MACD, moving averages, and positive performance against the S&P 500, with a year-to-date return of 30.18%.
Is Encompass Health Corp. overvalued or undervalued?
As of May 13, 2025, Encompass Health Corp. is considered very expensive and overvalued with a P/E ratio of 21, a Price to Book Value of 6.49, and an EV to EBITDA of 13.02, indicating that despite its growth potential, investors may be paying too much compared to its peers.
Who are in the management team of Encompass Health Corp.?
As of March 2022, the management team of Encompass Health Corp. includes Non-Executive Independent Chairman Leo Higdon, President and CEO Mark Tarr, and Independent Directors Gregory Carmichael, John Chidsey, Donald Correll, and Yvonne Curl, who oversee the company's strategic direction.
What does Encompass Health Corp. do?
Encompass Health Corporation provides post-acute healthcare services and operates in the mid-cap Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $1.455 billion and a net profit of $197 million, with a market cap of approximately $13.73 billion.
How big is Encompass Health Corp.?
As of Jun 18, Encompass Health Corp. has a market capitalization of $13.73 billion, with net sales of $5.51 billion and a net profit of $653.6 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
